Premium
Transurethral Visual Laser Ablation of the Prostate for Benign Prostatic Hyperplasia Using a KTP/YAG Laser
Author(s) -
Miki Tsuneharu,
Kojima Yasuyuki,
omura Norio,
Matsumiya Kiyomi,
Kokado Yukito,
Yoshioka Toshiaki,
Takahara Shirou,
Okuyama Akihiko
Publication year - 1997
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.1997.tb00312.x
Subject(s) - medicine , prostate , urology , hyperplasia , ablation , laser , laser ablation , laser therapy , optics , physics , cancer
Background : Transurethral visual laser ablation of the prostate (VLAP) has been established as an alternative method for the treatment of benign prostatic hyperplasia (BPH). However, most VLAP procedures utilize only a neodymium:yttrium‐aluminum‐gamet (Nd:YAC) laser. Since a potassiumtitenyl‐phosphate (KTP) laser offers limited tissue penetration, KTP can be safely utilized to excise part of the obstructing prostatic tissue. This study assessed the interaction between KTP vaporization and YAG coagulative ablation to determine the safety and efficacy of VLAP utilizing a combined KTP/YAG treatment. Methods : Forty patients with bladder outlet obstruction secondary to BPH were treated with VLAP using a KTP/YAG laser. The laser light was delivered by an angle delivery device. Results : Most cases demonstrated a significant improvement in routine subjective and objective parameters (AUA symptom score, peak flow rate, average flow rate, and amount of residual urine). No significant complications relating to this procedure were reported, however, 4 patients experienced postoperative acute urinary retention. Conclusion : KTP/YAG laser ablation of the prostate is safe and effective for the treatment of BPH.